Who Paid My Doc
A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy I
Research payments
$1,540,773
Through program year 2025, $1,540,773 in research payments was reported against A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy I, across 531 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $412,257 | 214 |
| 2024 | Research | $1,047,749 | 296 |
| 2023 | Research | $80,767 | 21 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Gary Buchschacher Los Angeles, CA Named on 108 payments
- Erika Maestas Albuquerque, NM Named on 44 payments
- Nilesh Verma Dallas, TX Named on 36 payments
- Meredith Pelster Nashville, TN Named on 35 payments
- Andrea Cercek Middletown, NJ Named on 28 payments
- Francis Farraye Jacksonville, FL Named on 17 payments
- Matthew Yurgelun Boston, MA Named on 15 payments
- Anteneh Tesfaye Washington, DC Named on 14 payments
- David Haas Nashville, TN Named on 14 payments
- Danielle Mishkin Quincy, MA Named on 14 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.